Erythropoietin Use In Patients with AML or Undergoing Allogeneic HSCT Significantly Improves Quality of Life and Reduces Red Blood Cells and Platelets Transfusions without Any Survival Effect.
Mauricette Michallet(Université Claude Bernard Lyon 1), Isabelle Jaisson‐Hot(Hôpital Lyon Sud), Stéphane Morisset(Lyon 1 Université), C. Pivot(Hôpital Lyon Sud), Fiorenza Barraco(Hôpital Lyon Sud), Youcef Chelghoum(Hôpital Edouard Herriot), Perrine Badol‐Van Straaten(Hôpital Lyon Sud), Karine Goldet(Hôpital Lyon Sud), Xavier Thomas(Hôpital Lyon Sud), Jean Vial(Hôpital Edouard Herriot), Franck E. Nicolini(Université Claude Bernard Lyon 1), C. Renzullo(Hôpital Lyon Sud), Mohamad Sobh(Ottawa Hospital), Carole Paillet(Hôpital Lyon Sud), Angélique Denis(Université Claude Bernard Lyon 1), Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Anne Termoz(Hôpital Lyon Sud)
Cited by 0
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547